Research programme: Chk1 kinase inhibitors - Galapagos/Avantogen

Drug Profile

Research programme: Chk1 kinase inhibitors - Galapagos/Avantogen

Alternative Names: Chk1 kinase inhibitors research programme - BioFocus/Avantogen

Latest Information Update: 13 Apr 2007

Price : $50

At a glance

  • Originator Avantogen; Galapagos NV
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; HIV infections

Most Recent Events

  • 13 Apr 2007 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
  • 13 Apr 2007 No development reported - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top